Grünenthals, NaV

Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development

Veröffentlicht: 17.03.2026 um 20:56 Uhr, prnewswire.co.uk

Grünenthal Group United Kingdom United States of America

View original content:https://www.prnewswire.co.uk/news-releases/grunenthals-proprietary-nav-1-8-inhibitor-enters-clinical-development-302691463.html

en | boerse | 68739502 |